《大行報告》瑞銀下調創科(00669.HK)目標價至160元 評級「買入」
瑞銀發表報告指,最近曾與創科(00669.HK)管理層溝通,管理層對旗下MWK增長指引為20%以上,因為專業工具需求繼續強勁。但與消費者相關的類別,包括DIY、戶外動力設備(OPE),以及地板護理等就因高通脹而放緩 。整體而言,管理層仍然有信心全年實現收入約10%增長和毛利率擴張50個基點。
創科本年至今股價累跌約47%後,瑞銀指其估值及風險回報具吸引力,特別是對長線投資者而言。經過近期股價調整後,目前股價對應預測2023年市盈率13倍,而2022年至2024年盈利複合增長率預測為16%。在疫情前創科估值相當於市盈率約15至20倍,平均盈利增長為15%。
瑞銀降創科2022至2024年各年每股盈測介乎8%至12%,以反映消費者類產品增長遜預期,目標價相應由175元下調至160元,評級「買入」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.